SRR1467011
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.414
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.339
- COAGULATION+0.332
- INFLAMMATORY_RESPONSE+0.321
- IL6_JAK_STAT3_SIGNALING+0.309
- PANCREAS_BETA_CELLS+0.291
- MYOGENESIS+0.273
- XENOBIOTIC_METABOLISM+0.271
- BILE_ACID_METABOLISM+0.259
- KRAS_SIGNALING_UP+0.236
Top 10 suppressed
- MYC_TARGETS_V1-0.634
- DNA_REPAIR-0.543
- MYC_TARGETS_V2-0.526
- PROTEIN_SECRETION-0.514
- UNFOLDED_PROTEIN_RESPONSE-0.513
- E2F_TARGETS-0.442
- MTORC1_SIGNALING-0.435
- CHOLESTEROL_HOMEOSTASIS-0.419
- G2M_CHECKPOINT-0.384
- UV_RESPONSE_UP-0.372
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1330699 | GTEX | — | 0.961 |
| 2 | SRR820292 | GTEX | — | 0.959 |
| 3 | SRR1444559 | GTEX | — | 0.958 |
| 4 | SRR817775 | GTEX | — | 0.957 |
| 5 | SRR819793 | GTEX | — | 0.953 |
| 6 | SRR1332856 | GTEX | — | 0.952 |
| 7 | SRR1455698 | GTEX | — | 0.949 |
| 8 | SRR1486863 | GTEX | — | 0.946 |
| 9 | SRR1330061 | GTEX | — | 0.940 |
| 10 | SRR1389036 | GTEX | — | 0.940 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.414 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.339 | Inavolisib | — uncovered |
| COAGULATION | 0.332 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.321 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.309 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.291 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.273 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.271 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.259 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.236 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.234 | Idelalisib | — uncovered |
| COMPLEMENT | 0.225 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.186 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.177 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.164 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.151 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.144 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.121 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.073 | Inavolisib | — uncovered |